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Abstract 
Purpose: To study the impact of an aqueous myrrh extract on the proliferation of cervical cancer cells in 
vitro.  
Methods: First, 100 g of ground myrrh resin was boiled in 1000 mL of distilled water for 30 min. 
Different components of the decoction were identified using gas chromatography–mass spectrometry 
and high-performance liquid chromatography. The effects of high (20 µg/mL) and low (10 µg/mL) 
concentrations of cisplatin, serial concentrations of myrrh (20, 40, 60, and 80 µg/mL), and a combination 
of both were evaluated using cell proliferation assay, DNA fragmentation, and electron microscopy.  
Results: All four myrrh concentrations decreased the viability of HeLa cells (16.25 % p < 0.01). A 
significant further decrease occurred when myrrh was combined with 10 µg/mL cisplatin (11.42 % p < 
0.01). This was confirmed by quantifying DNA fragmentation. Ultrastructurally, HeLa cells showed 
typical apoptosis after treatment with 10 µg/mL cisplatin or a high dose of myrrh. The use of 20 µg/mL 
cisplatin or the combined therapy resulted in cell necrosis with ruptured cell membranes and 
autophagosomes. The effect of combined therapy was more lethal than the effect of either of them 
alone.  
Conclusion: Myrrh induces apoptosis and autophagy and enhances the activity of cisplatin in vitro. It is 
potentially a basis for further studies of other types of cancer cell. The clinical use of myrrh in the 
palliative therapy of human cervical carcinoma might be justified. 
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Platinating agents, including cisplatin 
(CDDP), are therapeutic agents used in 
many types of cancer affecting the 
gonads, female genital system, and 
head and neck [1]. CDDP is often 
administered after surgery or radiation 
[2]. Patients receiving platinating agents 
can experience dose-dependent side 
effects resulting in permanent toxicity 
and morbidity [3]. Cancer cells can also 
develop resistance through decreased 
drug vitality, which requires metabolic 
induction, or due to changes in 
apoptosis-related proteins [4,5]. 
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Studies have examined the development 
of CDDP analogs to minimize its toxicity 
or resistance, which is crucial for the 
success of cancer chemotherapy [6]. 
Products extracted from species in the 
genus Commiphora have significant 
antibacterial, anti-inflammatory, and 
antitumor properties [7], in addition to 
their anti-proliferative effects in lung, 
pancreas, breast, and prostate cancers 
[8]. Therefore, this work evaluated the 
cytotoxic, apoptotic, autophagic, and 
chemosensitizing potential of the 
inexpensive medicinal plant, myrrh, 
alone and in combination with CDDP, on 
human cervical cancer cells in vitro using 
a cell proliferation assay, the 







HeLa cells (CCL-81) were purchased from ATCC 
(USA) and Dulbecco’s modified Eagle’s medium 
(DMEM) from Biochrom (Germany). CDDP was 
provided by the Gynecology Oncology Unit in 
King Abdulaziz University Hospital (KAUH). 
CDDP (Ebewe Pharma, Austria, 50 mg/100 mL) 
was prepared as a 3.3 mM stock solution [9]. 
Myrrh resin was purchased from a local 
merchant, cleaned, and ground. MTT [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide)] was from Sigma-Aldrich. 
 
Preparation of aqueous extract of myrrh 
 
First, 100 g of clean ground myrrh resin was 
added to 1000 mL of distilled water. The mixture 
was heated to boiling at 100 °C for 30 min. The 
decoction was centrifuged, filtered, frozen, and 
then lyophilized [10]. Then, 20 µg of the powder 
was dissolved in DMEM with 10 % fetal calf 
serum (FCS) before it was added to a monolayer 
of HeLa cells for 24 h. 
 
Gas chromatography–mass spectrometry 
(GC-MS) 
 
The analysis was performed using a GCMS-
QP2010 plus (Japan) and a DB-5 column (30 m 
× 0.25 mm i.d.; film thickness 1.00 μm) (USA). A 
1.0-μL sample of the aqueous extract was 
injected using splitless mode. Details of the 
procedure have been reported elsewhere [11]. 
 
High-performance liquid chromatography 
(HPLC) 
 
The aqueous extract was partitioned with diethyl 
ether using a separating funnel. The diethyl ether 
layer was evaporated under reduced pressure 
until dryness. The combined diethyl ether layers 
were evaporated and the resulting residue was 
dissolved in HPLC-grade methanol. Further 
technical details were as described previously 
[12]. 
 
HeLa cell culture 
 
First, 10 % fetal bovine serum (FBS) and 100 
µg/mL penicillin/streptomycin were added to the 
DMEM. For the culture and cytotoxicity 
experiments, 5 × 104 HeLa cells/well were added 
to 96­well plates in 5 % CO2–95 % air at 37 °C. 
Triplicate wells were prepared. 
 
Cell proliferation assay 
 
To evaluate the proliferation of HeLa cells, the 
MTT assay was used. MTT is reduced to purple 
formazan by mitochondrial dehydrogenase, 
indicating normally functioning mitochondria [13]. 
HeLa cells were incubated with increasing doses 
of CDDP (2.5, 5, 10, 20, and 40 μg/mL) for 24 h, 
and cell viability was assayed. Three 
independent experiments were performed in 
quintuplicate. CDDP had a dose-dependent anti-
proliferative effect on cell viability. The IC50 of 




Figure 1: Dose- and time-dependent curve of the 
inhibition rate (%) of cisplatin (μg/mL) on HeLa cells 
using MTT assay. Data are presented as mean ± SD 
of three independent experiments performed in 
quintuplicate. CDDP revealed a dose-dependent anti-
proliferative effect on cell viability. The IC50 of CDDP 
was 20 µg/ml after 24 hr 
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The medium was removed and replaced with 
high- (20 µg/mL) or low-dose (10 µg/mL) cisplatin 
solutions. Monolayer cells were also incubated 
with 20, 40, 60, and 80 µg/mL of the aqueous 
myrrh extract. Another group was incubated with 
10 µg/mL cisplatin and the serial doses of myrrh 
simultaneously. Cultured cells not subjected to 
any treatment acted as a control group. All wells 
were incubated for 24 h at 37 °C in 5 % CO2–95 
% air. The absorption of the culture plates was 
measured at 570 nm after 24 h in MTT using an 
ELISA reader (Bio-Rad) and compared with the 
control cultures. All experiments were performed 
three times. The viability of the cultured cells was 
calculated as in Eq 1. 
 
Viability (%) = {(At – Ac)/Ac}100 ……………. (1) 
 
where At and Ac are the absorbance of drug-
treated and control samples, respectively. 
 
Quantitation of DNA fragmentation 
 
DNA fragmentation in cultured cells was tested 
using the diphenylamine technique [14]. Cells (13 
× 106) were incubated for 18 h with or without 
CH-11 monoclonal antibody (100 ng/mL), 
collected, and washed with PBS. Total DNA was 
separated with 0.5 mL of lysis buffer {5 mM Tris-
HCl, 2 mM ethylenediaminetetraacetate (EDTA), 
0.5 % Triton X-100, pH 8.0}, and the lysate was 
centrifuged to separate high- from low-molecular-
weight DNA. The cleaved DNA in the 
supernatant was precipitated with 5 % 
trichloroacetic acid and the DNA fragments were 
quantified using spectrophotometry at 570 nm 
after adding diphenylamine.  
 
DNA fragmentation (%) was taken as the ratio of 
the amount of DNA in the supernatant to the total 
DNA in the supernatant and pellet, expressed as 
a percentage. 
 
Assessment of ultrastructural features 
 
The cell ultrastructure was studied using 
transmission electron microscopy, following the 
protocol of the King Fahd Medical Research 
Center at KAUH. When the cultured HeLa cells 
reached confluence, they were treated with 
trypsin diluted in phosphate-buffered saline 
(PBS) at a density of 200,000 cells per mL, and 
fixed in 2.5 % glutaraldehyde at room 
temperature for at least 2 h at 4 ºC. The cells 
were centrifuged three times until a pellet 
formed. The pellet was processed as described 
previously [15]. Grids were examined and 
photographed with a transmission electron 




The data were analyzed using SPSS version 22 
(IBM-USA). One-way analysis of variance 
(ANOVA) was used to determine the significance 
of differences. When equal variance was 
assumed, the least significant difference (LSD) t-
test was applied. The data are presented as the 
mean ± standard deviation (SD). P < 0.05 was 
considered statistically significant. 
RESULTS 
 
The different components of the decoction of 
myrrh obtained using GC-MS and HPLC are 
listed in Table 1. 
 
Table 1: Relative concentrations (%) of different 
chemical components of myrrh decoction 
  











There was a significant decrease in the viability 
of HeLa cells at all concen-trations of the 
aqueous extract of myrrh tested. Viability 
decreased by 16.25% on increasing the 
concentration from 20 to 80 µg/mL. In addition, 
cisplatin at both 20 and 10 µg/mL caused 
significant decreases in cell viability (50% and 
36%, respectively). The simultaneous combi-
nation of 10 µg/mL cisplatin and the serial 
concentrations of myrrh revealed a dose-
dependent decrease in cell viability. The greatest 
decrease was revealed upon combination with 
80 µg/mL myrrh (11.42 %) and was 35.6 % 
greater than that produced by the high 




To detect apoptosis, the DNA fragmentation was 
quantified. The use of myrrh alone increased the 
percentage of DNA fragmentation in a dose-
dependent manner. Cisplatin at 20 and 10 µg/mL 
induced 40.61 and 26.34 % DNA fragmentation, 
respectively. Moreover, the combined therapy of 
cisplatin and aqueous extract of myrrh enhanced 
DNA fragmentation and appeared to be more 
effective than cisplatin alone (Figure 3). 
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The ultrastructure of HeLa cells was studied 
using transmission electron microscopy. The 
untreated HeLa cells had intact plasma 
membranes with many microvilli; the nucleus had 
prominent nucleoli; and viable mitochondria were 
observed in the cytoplasm (Figure 4a).  
 
HeLa cells treated with 10 µg/mL Cisplatinwere 
typical apoptotic pyknotic cells with shrunken 
cytoplasm and condensed nuclear chromatin 
(Figure 4b). On increasing the dose of cisplatin to 
20 µg/mL, fragmentation of the nucleus, leakage 
of chromatin into the cytoplasm, development of 
autophago-somes, and rupture of the cell 
membrane were noted (Figure 4c). HeLa cells 
treated with the aqueous extract of myrrh 
contained clumps of nuclear chromatin and there 
was dilatation of the rough endoplasmic 
reticulum. Typical nuclear fragmentation was 
evident with higher doses (Figure 4d to Figure 
4g). Combining 10 µg/mL cisplatin and 
increasing serial doses of myrrh resulted in 
progressive condensation and leakage of 
chromatin, loss of integrity of the cytoplasmic 
organelles, and the presence of 
autophagosomes (Figure 4h Figure 4j). In 
addition, the combined therapy resulted in 
rupture of the plasma membrane of HeLa cells 
(Figure 4k). 
 
Figure 2: Cytotoxic effect of cisplatin and aqueous extract of myrrh on HeLa cells. The aqueous 
extract of myrrh caused a signif icant decrease in the viability of Hela cells at all concentrations. 
Simultaneous combination of 10 µg/mL cisplat in (Cis) and the serial concentrations of myrrh caused 
a dose-dependent decrease in cell viability. Untreated cells were used as a control (Cont). The 
results were analysed using one-way ANOVA followed by LSD post hoc test. Values are expressed 
as the mean ± SD 
 
Figure 3: Percentage of DNA fragmentation of hela cells using cisplatin (Cis) and aqueous myrrh 
(m) extract separately and in combination. There was high DNA fragmentation with combination 
therapy with 80 µg/ml myrrh (m) and 10 µg/ml Cis. Untreated cells were used as a control.  The 
results were analysed using one-way ANOVA followed by LSD post hoc test. Values are expressed 
as the mean ± SD 
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Figure 4: An electron micrograph showing the ultrastructural features of HeLa cells: (a) Untreated control group; 
(b, c) cells treated with 10 and 20 μg/mL cisplatin, respectively; (d–g) increasing doses of myrrh; and (h–k) both 
10 μg/mL cisplatin and increasing doses of myrrh. The untreated Hela cells had intact plasma membranes and 
numerous microvilli (thin arrows). Nuclear membrane was intact and there were prominent nucleoli (n). The 
cytoplasm contained many viable mitochondria (dashed arrows) (a). (b, c). Treatment with 10 and 20 µg/mL 
cisplatin produced typical apoptotic pyknotic cells with shrunken cytoplasm and condensed nuclear chromatin (N) 
(b), while in (c) there was fragmentation of the nucleus, leakage of chromatin into the cytoplasm, and cell 
membrane rupture. (d-g) Treatment with increasing doses of myrrh resulted in clumps of nuclear chromatin and 
dilatation of the rough endoplasmic reticulum. (h-k) Treatment with 10 µg/mL Cisplatin and increasing serial 
doses of myrrh resulted in progressive condensation and leakage of chromatin ©, loss of integrity of the 




This study used HeLa cells as a model 
to evaluate the therapeutic mechanism 
of myrrh in human cervical cancer by 
investigating its cytotoxic, apoptotic, and 
autophagic potential in comparison with 
CDDP. 
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Myrrh alone caused a concentration-
dependent decrease in the viability of 
HeLa cells. In addition, the concentration 
of CDDP had a profound effect, 
decreasing the cell viability to 11.42 %. 
Apoptotic effects were confirmed by the 
DNA fragmentation assay. 
 
A previous study found that the majority 
of patients with cancer use 
complementary and alternative medicine 
(CAM); however, CAM is usually not 
effectively integrated with conventional 
oncology treatment (COT) [16]. 
 
The constituents of the decoction of 
myrrh included sesquiterpenes, such as 
α-cadinene, 2-methoxyfuranodiene, 
cuminaldehyde, and 3-epi-α-amyrin. In 
trials to induce cancer cell apoptosis, 
sesquiterpenes arrested the cell cycle at 
the G0/G1 phase in prostate cancer cells. 
Both the antiproliferative and the 
immune/inflamma-tory-modulating 
effects of myrrh were attributed to 
sesquiterpenes [17]. 
 
Physicochemical assays in vitro 
characterized these components as 
antioxidants. Nevertheless, they were 
described as cytotoxic. This was 
explained based on the cell membrane 
damage and permeability of its different 
layers, in addition to a decrease in the 
mitochondrial membrane potential 
leading to membrane depolarization [18] 
and a reduction in the pH gradient 
resulting in the seepage of cytochrome 
C, calcium ions, and proteins [19]. 
 
The ultrastructural morphology of HeLa 
cells revealed signs of apoptosis using 
either (10 µg/mL) cisplatin or myrrh, 
while features of necrotic cell death were 
obvious with the higher dose of cisplatin 
or the combined treatment. In 
accordance with these results, it was 
reported that cisplatin can induce either 
apoptosis or necrosis depending on the 
dose [20] and the metabolic and energy 
status of the cells [21]. 
 
Autophagosomes were also seen with 
the combined treatment. Autophagy may 
act as a therapeutic mechanism to 
suppress cancer or as an adaptive 
mechanism to protect cells from 
chemotherapy. The interaction between 
the microenvironment and autophagy is 
a complicated process [22]. The 
interactive link between apoptosis and 
autophagy has been documented and it 
has been reported that the same factors 
induce autophagy and apoptosis [23]. 
p53, a powerful motivator of apoptosis, 
can also drive autophagy. Autophagy 
increases DRAM, a direct p53 target 
gene [24]. In addition, activation of the 
PI3 kinase/Akt pathway inhibits both 
apoptosis and autophagy [25]. Various 
biochemotherapeutic combinations have 
been developed to combine the cytotoxic 
action of cancer chemotherapy with 
substances that modulate the antitumor 
biological response. This is in addition to 
counteracting the suppressive effect of 
cancer chemotherapy on host 
immune/biological responses, which has 
a dominant effect in tumor progression 
[26]. Natural molecules isolated from 
myrrh have both immunostimulatory 
activity and anti-proliferative and 
antioxidant effects [27]. This could 
improve the efficacy and tolerability of 




The findings of this study indicate that 
the use of myrrh alone and in 
combination with CDDP leads to 
apoptosis and autophagy. This is 
probably the basis for further studies of 
the effects on the survival of HeLa cells. 
The clinical use of myrrh in the palliative 
therapy of human cervical carcinoma 
may be justified. 
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